Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Thyroid Cancer: early-phase trial registry
25 of 48 indexed Thyroid Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #297 of 28,707 conditions by registered trial count.
48 US clinical trials · 25 currently recruiting · #297 of 28,707 conditions by registered trial count
Thyroid Cancer: 48 US clinical trials tracked, 25 recruiting.
Thyroid Cancer is the subject of 48 registered US clinical trials on ClinicalTrials.gov, 25 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 12 of these trials.
Enrollment posture brief
Registry condition thyroid-cancer
OPEN 25 | RECR 52% | LATE 3 | EARLY 24 | RANK #297 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Amblyopia (52% recruiting · 25 trials)
Thyroid Cancer lists 25 open slots (52% of 48 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Thyroid Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Thyroid Cancer is recruiting above its size-band peers.
25 of 48 indexed trials (52.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Thyroid Cancer research.
Memorial Sloan Kettering Cancer Center accounts for 12 of 48 trials (25%). 31 distinct sponsors appear on at least one study for this condition label.
-
Typical Thyroid Cancer enrolment sits around 60 participants.
Median target enrolment is 60 among the 47 trials that report a genuine target (sentinel values excluded). 28 of those (59.6%) plan for fewer than 100 participants.
-
Thyroid Cancer research is mostly interventional.
35 interventional and 13 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
48 total, page 1 of 1
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
Studies on Tumors of the Thyroid
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001160
Environmental Factors and Thyroid Cancer
Icahn School of Medicine at Mount Sinai
NCT05172921
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
M.D. Anderson Cancer Center
NCT06507878
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
Georgetown University
NCT06980103
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
NCT04916990
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
NCT05355701
Hereditary Risk Factors for Thyroid Cancer
Dana-Farber Cancer Institute
NCT02747888
New MRI Biomarkers in Head and Neck Cancers
Memorial Sloan Kettering Cancer Center
NCT03483337
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT05733013
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
Vanderbilt University Medical Center
NCT05999630
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT06771219
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
Thomas Hope
NCT06961084
Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery
Thomas Jefferson University
NCT06918223
I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer
Miami Cancer Research Center
NCT06443866
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
M.D. Anderson Cancer Center
NCT06959511
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
NCT07092514
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03841617
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
NCT05668962
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT06007924
TRAIL Study: Feasibility and Pilot
Dartmouth-Hitchcock Medical Center
NCT06220656
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
UNC Lineberger Comprehensive Cancer Center
NCT06902376
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
Personalized Treatment in Thyroid Disorders
Johns Hopkins University
NCT03517579
Mortality Benefit of Ultrasound for Thyroid Nodules Identified With PET Imaging: Non-Inferiority Emulated Target Trial
Brigham and Women's Hospital
NCT07255482
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
Measuring Patient Expectations for Thyroid Surgery
Memorial Sloan Kettering Cancer Center
NCT01412762
A Study of Optical Imaging With Light From Radiotracers in Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT03484884
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
University of Chicago
NCT03360890
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT01141309
CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
The Cleveland Clinic
NCT04495985
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
NCT01709292
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT04544111
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT04238624
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
NCT05119296
RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
Memorial Sloan Kettering Cancer Center
NCT03215095
Laser Ablation of Papillary Thyroid Microcarcinoma
Memorial Sloan Kettering Cancer Center
NCT04623801
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Dana-Farber Cancer Institute
NCT02657551
Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT03196518
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
Eisai
NCT01321554
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
Exelixis
NCT00704730
Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT03300284
Molecular Testing to Direct Extent of Initial Thyroid Surgery
University of Pittsburgh
NCT02947035
Effect of Childhood Radioiodine Therapy on Salivary Function
Boston Children's Hospital
NCT02375451
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Eisai
NCT00124527
Energy Metabolism in Thyroidectomized Patients
Virginia Commonwealth University
NCT04782856
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 17 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Thyroid Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Thyroid Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Thyroid Cancer page
48 registered trials, 25 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 25 Thyroid Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Thyroid Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thyroid Cancer condition card totals 48 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.